Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6072245 | 0.93 | JAK2 (0.31) | IRAK4 | |
| SCHEMBL6072134 | 0.91 | IRAK4 (0.32) | IRAK4 | |
| Hydrochloric Acid SCHEMBL6072006 | 0.88 | SSTR5 (0.32) | — | |
| SCHEMBL6071808 | 0.87 | GAA (0.33) | IRAK4 | |
| SCHEMBL6071593 | 0.87 | ALDH1A1 (0.34) | IRAK4 | |
| Hydrochloric Acid SCHEMBL6071761 | 0.87 | GAA (0.33) | IRAK4 | |
| Hydrochloric Acid SCHEMBL6072452 | 0.86 | CXCR2 (0.34) | CXCR2 | |
| Hydrochloric Acid SCHEMBL5785728 | 0.85 | MRGPRX4 (0.34) | IRAK4 | |
| Hydrochloric Acid SCHEMBL6072326 | 0.85 | MAPT (0.39) | IRAK4 | |
| SCHEMBL5784342 | 0.82 | IRAK4 (0.32) | IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060106048-A1 | Furoisoquinoline derivative and use thereof | PASCALI, PETROS P. (CY) | 2006-05-18 | — | — | US | disclosed |
| EP-1541576-A1 | FUROISOQUINOLINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106048-A1 | Furoisoquinoline derivative and use thereof | PDE3B, PDE2A, PDE3A | CXCR2 2009/4885IRAK4 1857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.